Martin R.
- Country
- Germany
- Department
- Onkologie
Research Overview
- Phase 3 Randomized Study of Nivolumab and Ipilimumab with Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer
- Tarlatamab plus Durvalumab versus Durvalumab Alone in Patients with Extensive-Stage Small Cell Lung Cancer Following Platinum-Etoposide Therapy
- Efficacy and Safety of PF-08634404 Plus Combination Therapy Versus Pembrolizumab Plus Combination Therapy in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 515 of 772 partner sites.
Specializations
Non-Small Cell Lung Cancer (NSCLC)
The investigator specializes in evaluating novel therapeutic approaches for advanced and metastatic NSCLC, with particular focus on immunotherapy combinations and targeted treatments.
- PD-L1 expression targeted therapies
- EGFR mutation specific treatments
- Neoadjuvant therapy approaches
Research encompasses both early-stage resectable disease and advanced metastatic settings.
Small Cell Lung Cancer (SCLC)
The investigator conducts research in extensive-stage SCLC, focusing on innovative combination therapies and maintenance treatment strategies.
- Novel immunotherapy combinations
- Maintenance therapy approaches
- Second-line treatment options
Studies include evaluation of both single-agent and combination therapeutic strategies.
Specialized Lung Cancer Subtypes
The investigator works with distinct lung cancer populations including large cell neuroendocrine carcinoma and specific molecular subtypes.
- KRAS G12C mutations
- RET fusion-positive cases
- TTF-1 negative adenocarcinoma
Focus includes both rare subtypes and molecular-defined patient populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.